ArticleFrontiers in oncology2022

CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated

Stefania Napolitano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.